Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation

Chest

Volumn 140, Issue 4, 2011, Pages 918-924

  Poli, Daniela ^a   Testa, Sophie ^c   Antonucci, Emilia ^b   Grifoni, Elisa ^b   Paoletti, Oriana ^c   Lip, Gregory Y H ^d  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CREMONA HOSPITAL   (Italy)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED CANCER; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

EID: 80053530548     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-3024     Document Type: Article

References (25)

1. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007; 6 (11):981-993. (Pubitemid 47566414)
2. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007; 69 (6):546-554.
3. Hughes M, Lip GY; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008; 99 (2):295-304. (Pubitemid 351230959)
4. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009; 151 (5):297-305.
5. Rosendaal FR, Cannegieter SC, Van der Meer FJM, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69 (3):236-239. (Pubitemid 23069000)
6. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003; 26 (suppl 1):S5-S20.
7. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154 (13):1449-1457.
8. Singer DE, Albers GW, Dalen JE, et al American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation. American College of Chest Physicians Evidencebased Clinical Practice Guidelines (8th edition). Chest. 2008; 133 (s uppl 6):546S-592S.
9. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285 (22):2864-2870. (Pubitemid 32537350)
10. Atrial Fibrillation: NICE Guidelines. National Institute for Health and Clinical Excellence Web site. 2006. http://www. nice.org.uk/CG36/guidance. Accessed March 30, 2010.
11. Fuster V, Rydén LE, Cannom DS, et al American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114 (7):e257-e354.
12. Rietbrock S, Heeley E, Plumb J, Van Staa T. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age > 75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS 2) risk stratification scheme. Am Heart J. 2008; 156 (1):57-64. (Pubitemid 351877101)
13. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998; 105 (2):91-99. (Pubitemid 28405230)
14. Palareti G, Leali N, Coccheri S, et al Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996; 348 (9025):423-428. (Pubitemid 26267872)
15. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998; 280 (19):1690-1691. (Pubitemid 28532993)
16. Gage BF, Van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004; 110 (16):2287-2292. (Pubitemid 39407328)
17. Baruch L, Gage BF, Horrow J, et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke. 2007; 38 (9):2459-2463. (Pubitemid 47329622)
18. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008; 39(6):1901- 1910.
19. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost. 2009; 101(2):367- 372.
20. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137 (2):263-272.
21. 2 score = 1. Thromb Haemost. 2010; 103 (4):833-840.
22. Connolly SJ, Pogue J, Eikelboom J, et al; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008; 118 (20):2029-2037.
23. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007; 115 (21):2689-2696. (Pubitemid 46842784)
24. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol. 2009; 54 (11):999-1002.
25. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anti-coagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004; 141 (10):745-752.